China’s First Genetic Engineering Pharmaceutical Base To Begin Operations in 2010
This article was originally published in PharmAsia News
Executive Summary
China's first national genetic engineering pharmaceutical base will begin operating next year in Changchun city, in northeastern China. Covering 45,000 square meters, the RMB 330 million base, funded by GeneScience Pharmaceuticals, will produce more than 10 types of patented products including genetically engineered thymosin, long-acting growth hormone and follicle-stimulating hormone. The facility's revenue is expected to reach RMB 2 billion within five years after its launch, and to climb to RMB 5 billion within eight years. While adopting advanced international standards, the facility is set to boost China's biopharmaceutical industry. (Click here for more - Chinese Language)